Summit Therapeutics Inc.

Summit Therapeutics Inc.

290.00
MXN
0.00
(0.00%)
-19.29EPS
Mar 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.28
0.01
- -
- -
0.06
0.27
0.87
0.01
0.02
- -
- -
- -
- -
- -
Basic EPS, GAAP
-2.99
-0.04
-2.09
-0.69
-0.55
-0.44
0.17
-0.76
-0.96
-0.41
-0.99
-0.31
-1.44
-1.07
Free Cash Flow per Basic Share
-2.31
-0.04
-2.02
-0.59
0.31
-0.32
-0.54
-0.7
-0.79
-0.22
-0.12
-0.2
-0.43
-0.68
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.02
2.68
2.37
2.66
-0.44
-0.3
2.28
0.96
0.85
0.6
0.11
0.53
0.85
0.71
Tangible Book Value per Share
1.9
0.34
1.62
1.98
-0.97
-1.96
1.61
0.8
0.72
0.59
0.11
0.52
0.85
0.7
Basic Weighted Avg Shares
4
409
8
59
62
65
86
69
92
193
620
719
748
780
Sales/Revenue/Turnover
5
4
- -
- -
4
17
75
1
2
1
- -
- -
- -
- -
Operating Margin (%)
-252.04
-487.93
- -
- -
-1,055.56
-192.58
17.45
-6,081.63
-4,763.68
-9,024.26
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
1
3
2
2
1
- -
- -
- -
- -
Net Income, GAAP
-11
-17
-17
-41
-34
-29
14
-53
-89
-79
-615
-221
-1,080
-833
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-232.91
-443.13
- -
- -
-927.56
-163.09
19.04
-6,127.56
-4,897.84
-11,174.75
- -
- -
- -
- -
Working Capital
7
3
18
36
35
18
58
68
72
618
169
382
647
551
LT Debt
- -
- -
- -
- -
- -
1
1
- -
2
497
103
3
18
16
Total Equity
7
13
20
33
-5
-4
73
79
83
127
78
389
659
565
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-161.61
-164.78
-105.72
-156.66
- -
- -
- -
-69.07
-108.89
-75.05
-601.85
-94.9
-206.1
-220.01

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
17
17
16
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
776
793
800
Market Capitalization
12,312
13,308
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
617
721
661
Cash, Cash Equivalents & STI
599
691
630
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
83
104
110
Payables & Accruals
72
88
89
ST Debt
3
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-131.14%
97.62%
69.48%
Free Cash Flow
16.91%
60.55%
127.49%
Net Income, GAAP
54.7%
212.28%
387.81%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
-0.09
-0.08
-0.08
-0.31
2025
-0.09
-0.76
-0.31
-0.29
-1.44
2026
-0.24
-0.28
-0.26
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Robert W. Duggan
Full Time Employees
265
Sector
Health technology
Industry
Biotechnology
Address
601 Brickell Key Drive Miami FL United States 33131
IPO Date
Oct 14, 2004
Website
smmttx.com
Business
Summit Therapeutics Inc. (Nasdaq: SMMT) is a biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies. The company develops ivonescimab, a novel bispecific antibody combining PD-1 blockade for immunotherapy with anti-VEGF-mediated anti-angiogenesis effects; ivonescimab is in global Phase III clinical trials, including HARMONi and HARMONi-3 for EGFR-mutated non-small cell lung cancer (NSCLC), HARMONi-6 for squamous NSCLC, HARMONi-7, and the recently announced HARMONi-GI3 for first-line metastatic colorectal cancer, with over 2,800 patients treated to date across trials. Summit holds exclusive licenses for ivonescimab in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa, while partner Akeso, Inc. retains rights in other regions and conducts trials in China and Australia. Founded in 2003 and headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK, the company targets solid tumors such as NSCLC and colorectal cancer. Recent developments include a $500 million private placement in October 2025 to fund operations and U.S. trial site openings for HARMONi-GI3 by year-end; collaborations with Pfizer to combine ivonescimab with antibody-drug conjugates and with Revolution Medicines for RAS(ON) inhibitors in NSCLC, pancreatic ductal adenocarcinoma, and colorectal cancer; positive HARMONi-6 top-line results in 2025 showing a 40% reduction in progression or death risk in squamous NSCLC; and completion of HARMONi enrollment with favorable survival trends in Western patients.

Company News

  • Summit Stock Falls on FDA Rejection for Lung Cancer Drug

  • 2 Cancer-Drug Developers Seeing Unusual Options Volume

  • Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs

  • Breakfast News: Summit’s FDA Setback Isn’t the End

  • Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles

  • FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

  • Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

  • Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?

  • SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus

  • Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

  • Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts

  • Breakfast News: Science Strikes Back at Cancer

  • Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S

  • Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China

  • Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

  • Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

  • Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

  • Summit Expands Ivonescimab Development Into Biliary Tract Cancer

  • Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

  • Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?